Kornimate/medical-research-clean huggingface dataset:
spirituality, experience of disease and quality of life in cancer patients

Conditions: Psychology and Cancer

Summary: the general aim of research is to identify and analyze the impact and role of spirituality (as a search for meaning and understanding of the meaning of existence) in the experience of cancer. for this purpose, the main objective of this study is to measure the "existential" component in the trajectory of the disease. it is a question of observing its potential contribution to the improvement of the quality of life of the patients and to define if this variable can be translated into a strategy of adjustment for the patients. this research has a double interest: (a) clinical interest in better managing patients' needs; (b) an interest in research in the field of health by combining a measure of spirituality with other psycho-social variables. the project is a prospective non-randomized mono-centric study by questionnaire and research interview. it is a study that seeks to identify the role of spirituality in the experience of illness (i.e. representations, adjustments, emotional distress) and as a determinant of the quality of life of subjects with cancer pathology. the interviews will be conducted by a psychologist to qualitatively collect the elements of the lived experience of the disease in connection with the spiritual elements of the "quest for meaning" type. the population covered by the project is in and out patients coming to the department of medical oncology and palliative care at the chu de la timone. the realization of this project will allow investigators to explore the specificity of the existential / spiritual dimensions of patients confronted with cancer, to assess the patients' needs for this type of approach within the hospital, to link the existential component / spiritual with psycho-social variables


Eligibility criteria:
inclusion criteria: * patient undergoing chemotherapy exclusion criteria: * patient presenting psychiatric or neurological disorders
topical calcipotriol /betamethasone ointment in the treatment of plaque psoriasis

Conditions: Psoriasis Vulgaris; Fractional CO2 Laser

Summary: comparing the clinical efficacy of topical ointment containing calcipotriol and betamethasone dipropionate used alone with the simultaneous use of fractional carbon dioxide laser and the same topical ointment containing these two ingredients as treatment modalities for plaque psoriasis. additionally, looking into how both therapy modalities affect individuals with psoriasis in terms of how their quality of life is improved.

psoriasis is a widespread, persistent papulosquamous skin condition that can affect anyone at any age and places a heavy strain on both the individual and society. it is linked to a number of serious medical disorders, such as cardiometabolic syndrome, depression, and psoriatic arthritis (1). patients with psoriasis indicate that the condition interferes with their ability to sleep and rest, limits their everyday activities, particularly their mobility, and stigmatises them and causes problems in their social lives. additionally, psoriasis can negatively impact mental health. many psoriasis sufferers struggle with addiction, anxiety, and depression (2, 3). topical medicines continue to be the basis of treatment for those with mild psoriasis, and they include topical corticosteroids, vitamin d analogues, calcineurin inhibitors, and keratolytics (4). for the topical management of mild psoriasis, preparations containing calcipotriol in combination with betamethasone (in the form of betamethasone dipropionate) are available (5). in comparison to the effects of these active substances when given separately, pharmacodynamic investigations demonstrated the synergy between the anti-inflammatory and immunoregulatory actions of calcipotriol and betamethasone dipropionate (6). the synergistic activity of the two drugs is what makes calcipotriol/betamethasone dipropionate combinations successful. betamethasone impacts inflammatory processes and lessens skin irritation and pruritus following calcipotriol administration, while calcipotriol alters keratinocyte differentiation (7). fractional lasers were used in the treatment of dermatological diseases. they create tiny ablation channels in the skin that act as shunts for topically applied medications, particularly those with high molecular weights (8), by ablation of the skin in the form of fractions and splitting laser beams into microbeams (9).

Eligibility criteria:
inclusion criteria: * patients with chronic plaque psoriasis of either sex. * aged more than 18 years of age. exclusion criteria: * pregnant and lactating women. * patients with severe skin infection. * patients who are under systemic ttt or phototherapy in the last 3 months. * immunosuppression or being under any kind of treatment causingabsolute or relative immunosuppression * history of any bleeding, clotting disorder or using anticoagulants. * chronic systemic diseases such as chronic renal failure, hepatic insufficiency, and cardiovascular disorders.

Keywords: psoriasis vulgaris fractional co2 laser calcipotriol /betamethasone ointment
milrinone on cardiac performance during off-pump coronary artery bypass surgery

Conditions: Ischemic Heart Disease

Summary: the purpose of this study is to analyze the changes in cardiac performance before and after milrinone administration in order to find out whether milrinone improves lv performance in patients undergoing coronary artery bypass surgery.


Eligibility criteria:
inclusion criteria: * patient agree and provide written informed consent. * patient undergoing elective coronary artery bypass graft surgery * preoperative lv ef\>50% (tte) exclusion criteria: * preoperative cardiac dysrhythmia * preoperative iabp * use of other inotropic agents

Keywords: milrinone diastolic function
a study to assess the long-term safety and efficacy of lebrikizumab (ly3650150) in participants 6 months to <18 years of age with moderate-to-severe atopic dermatitis

Conditions: Atopic Dermatitis; Eczema

Summary: the main purpose of this study is to assess the long-term safety and efficacy of lebrikizumab in participants 6 months to \<18 years of age with moderate-to-severe atopic dermatitis. this study will last about 68 weeks and may include up to 16 planned visits. if participating in the optional extension as well, the study will last approximately 1 additional year for a total of up to 116 weeks and may include up to 29 scheduled visits.


Eligibility criteria:
inclusion criteria: * received treatment in study kgbi and have adequately completed the study treatments and last visit of study kgbi, including any applicable systemic ad treatment washout. * for female participants of childbearing potential, highly effective contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies exclusion criteria: * developed an serious adverse events (sae) during their participation in parent study kgbi deemed related to lebrikizumab, which in the opinion of the investigator or of the medical monitor could indicate that continued treatment with lebrikizumab may present an unreasonable risk for the participant. * developed an ae during their participation in the study kgbi that was deemed related to lebrikizumab and led to study treatment discontinuation, which in the opinion of the investigator or of the medical monitor could indicate that continued treatment with lebrikizumab may present an unreasonable risk for the participant. * met the criteria for permanent study intervention discontinuation in study kgbi, if deemed related to lebrikizumab or led to investigator- or sponsor-initiated withdrawal of participant from the study (for example, noncompliance, inability to complete study assessments, etc.) note: if study kgbi is still blinded at the time of rollover to study kgbj, conditions deemed related to the study treatment will be considered related to lebrikizumab. * are pregnant or breastfeeding or are planning to become pregnant or breastfeed during the study.
a study to evaluate itca 650 compared to glimepiride for the treatment of type 2 diabetes

Conditions: Type 2 Diabetes

Summary: phase 3 study to examine treatment with itca 650 compared to glimepiride when added to metformin monotherapy in reducing hba1c in patients with type 2 diabetes.


Eligibility criteria:
inclusion criteria: * hba1c between 7.5% - 10.5% * on metformin monotherapy * bmi between 25 \& 45 kg/m2 exclusion criteria: * on thiazolidinedione, sulfonylureas, dpp-4, exenatide, alpha glucosidase inhibitors, meglitinides or insulin within last 3 months * history of pancreatitis
optimizing the management of flares in patients with rheumatoid arthritis (ra)

Conditions: Rheumatoid Arthritis

Summary: the purpose of this study is to determine how best to monitor for flares in patients with rheumatoid arthritis (ra).

this project is aimed at developing an improved multilevel care process model for the management of rheumatoid arthritis (ra) disease activity by implementing systematic self-monitoring of flare experiences by ra patients, combined with continuous patient-tailored adjustments of treatment modalities by a coordinated team of rheumatology health care providers (rhcps).

Eligibility criteria:
inclusion criteria * patient must be ≥ 18 years of age. * patient must have been seen by a rheumatology health care provider at least two times within the last 18 months at mayo clinic rochester. * patient must have rheumatoid arthritis (ra) according to the 2010 acr/eular classification criteria. * patient must have the ability to understand and the willingness to sign a written informed consent document. * patient must be willing to return to mayo clinic rochester for follow-up appointments and fill out questionnaires as outlined in the study.

Keywords: rheumatoid arthritis disease activity flare management of flares pfizer
non-inferiority phase iii trial comparing dapaconazole cream 2% with ketoconazole cream 2% in patients with tinea pedis

Conditions: Tinea Pedis

Summary: this is a non-inferiority, phase iii, open-label, randomized, parallel trial to evaluate the new intervention dapaconazole cream 2% versus ketoconazole cream 2% in patients with tinea pedis. sample size is 140 participants (70 per treatment group), male or female, aged between 16 and 60 years-old. primary objective is to evaluate non-inferiority of dapaconazole cream 2% compared to ketoconazole cream 2% in tinea pedis treatment. secondary objective is to evaluate safety and tolerability of dapaconazole cream 2% after multiple administrations. participants will receive either new intervention or active control during 14 consecutive days, which will be followed by 2 follow-up visits. primary efficacy endpoint is clinical and mycological lesion cure, and secondary efficacy endpoint is time (days) until clinical diagnosis of lesion cure. additionally, safety will be assessed by adverse events occurrence and laboratory exams evaluation.


Eligibility criteria:
inclusion criteria: * male or female study participants, aged between 16 and 60 years-old. patients aged between 16 and 18 years-old will provide additional assent form before enrollment in the trial; * presence of a skin lesion characteristic of tinea pedis, with diagnosis confirmed by direct mycological exam; * absence of previous antifungic treatment for the lesion under study; * absence of other significant diseases which, at the physician's discretion, could have an impact on subject's participation in the trial, according to protocol requirements, and study evaluations: medical history, blood pressure and heart rate measurements, physical examination and screening laboratory tests; * ability to understand the nature and objectives of the trial, including risks and adverse events; willingness to cooperate with the researcher and proceed according to all study requirements, which shall be confirmed by informed consent form signature. exclusion criteria: * known hypersensitivity to ketoconazole or chemically related compounds; history of serious adverse reactions; * screening laboratory tests results showing clinically relevant deviations that, at the researcher discretion, prevent the subject to participate in the trial due to possible risks; * drugs addiction, including alcohol; * use of any previous treatment to the lesion under study that, according to principal investigator best judgement, might interfere in study objectives; * treatment, within 3 months before the trial, with any drugs known to have a well-established toxic potential to major organs; * participation in any other experimental research or administration of any experimental drug within 6 months before this trial; * pregnancy, labor or miscarriage with 12 weeks before study treatment; * any conditions, according to investigator's best judgement, that prevents the subject to participate in the trial.
dual-process mechanisms of action for sipit intervention effects in patients with urolithiasis

Conditions: Kidney Stone; Urolithiasis; Nephrolithiasis

Summary: the purpose of this study is to clarify the fundamental processes underlying behavior change, maintenance, and adherence during and after a 3-month fluid intake intervention period.

the study is a six-month ecological momentary assessment study of patients using the mini-sipit intervention for 3 months, with weekly assessments of motivation and life events or stressors that disrupt routines during the 3-month intervention period, and monthly assessments of motivation and life events or stressors that disrupt routines in the three months following the end of intervention (months 4-6). the mini-sipit intervention includes automated and manual tracking of fluid intake and lapse-contingent reminders to drink.

Eligibility criteria:
inclusion criteria: * previous diagnosis of symptomatic kidney stone in the past 5 years, * age 18 or older, * own an ios or android smart phone, * proficient in english, * capable of providing informed consent, * willing to use the water bottle and companion app \& receive text message reminders for 3 months, * live in continental us. exclusion criteria: * pregnant or planning to become pregnant during the next 6 months, * concurrently participating in other study involving fluid intake or diet, * plan to have surgery in the next 6 months, * co-morbidities that preclude high fluid intake (congestive heart failure, end-stage renal disease, chronic hyponatremia), or * active medical treatments that would impair protocol compliance.
patient-derived organoids drug screen in pancreatic cancer

Conditions: Pancreas Cancer; Pancreas Neoplasm; Pancreas Adenocarcinoma; Pancreatic Cancer; Pancreatic Neoplasms; Pancreatic Adenocarcinoma

Summary: few chemotherapeutic options exist for pancreatic cancer. moreover, objective criteria are lacking for deciding which regimen is more beneficial for patient presenting with metastases at diagnosis. this study investigates whether organoid generation from tumour samples of pancreatic cancer is a safe and feasible process for testing of multiple chemotherapy regimens in the laboratory. by participating to this study, patients will have a part of the tumour tissue retrieved and sent to the laboratory for organoid generation and drug testing. for surgically-resectable tumors, tumoral tissue samples will be collected from the main surgical specimens, before sending it for final pathological examination. in case of suspected metastatic lesion at diagnosis, curative surgery is not indicated. therefore, we will offer patients to undergo port-a-cath implantation for chemotherapy delivery and concomitant laparoscopic surgical excisional biopsy of suspicious metastatic (either hepatic or peritoneal) lesions. at this stage of the study, the treatment that the patient will receive after surgery will not be affected by the results of the laboratory testing. in fact, all patients will receive the standard of care treatment based on the most recent oncologic guidelines and on the oncologist's clinical judgement. as part of the study, each patient will be followed for 30 days to assess possible surgical complications related to the surgical biopsy. this study will help to speed up the implementation of organoid generation in the clinical routine for the choice of the best treatment of patients affected by pancreatic cancer.


Eligibility criteria:
inclusion criteria: * written informed consent provided * patients older than 18 years * histologically- or cytologically-proven pancreatic ductal adenocarcinoma (pdac) * tumour lesion amenable for laparoscopic, surgical biopsy * eastern cooperative oncology group (ecog) performance status (ps) 0-2 * radiologically measurable disease * life expectancy \> 3 months * absolute neutrophile count \>1500/microl, platelets \>100'000/microl * serum creatinine \ 50ml/min (according to the chronic kidney disease epidemiology collaboration (ckd-epi) formula) exclusion criteria: * concomitant need for full anticoagulation that cannot be interrupted or bridged prior to tissue biopsy * ecog ps \>2 * heart failure (nyha class iii-iv) * severe or uncontrolled concurrent illness * myocardial infarction within the previous 6 months
the efficacy and safety of transcranial temporal interference stimulation (ttis) targeting the right globus pallidus internus (gpi) for motor symptoms in patients with pd

Conditions: Temporal Interference Stimulation; Parkinson's Disease; the Right Globus Pallidus Internus; Motor Symptoms

Summary: to demonstrate that intervention targeting the right globus pallidus internus (gpi) using transcranial temporal interference stimulation can improve motor symptoms in patients with parkinson's disease.

each of patients received either 30-minute or sham ttis of the right gpi. before and immediately after the stimulation, participants completed the movement disorder society-unified parkinson's disease rating scale (mds-updrs-iii) in the "medication-on" state to assess the motor symptoms. mds-updrs, hama and hamd were assessed on intervention day 1, day 10 and 1-month follow-up and clinical efficacy was evaluated by comparing the scale scores before and after the intervention.

Eligibility criteria:
inclusion criteria: 1. meeting the diagnostic criteria for parkinson's disease in china (2016 version), diagnosed as pd by two neurologists; 2. hoehn-yahr stage 1.5-4; 3. age \> 50 years old; 4. no signs of moderate to severe depression: beck depression inventory-ii (bdi-ii) score \< 20; 5. no signs of dementia: mini-mental state examination (mmse) score \> 21; 6. no change in medication regimen in the four weeks prior to enrollment; 7. right-handed. exclusion criteria: 1. history of other neuropsychiatric disorders; 2. history of alcohol or drug abuse; 3. previous history of tms or traditional tes treatment; 4. presence of non-mri compatible metal implants in the body, such as deep brain stimulation devices, pacemakers or stents.

Keywords: temporal interference stimulation parkinson's disease motor symptoms the right globus pallidus internus
efficacy and safety of jinshuibao for patients with chronic kidney disease due to glomerulonephritis

Conditions: Chronic Kidney Disease Stage 3B; Chronic Kidney Disease stage4; Glomerulonephritis

Summary: this is a multicenter, double-blind randomized controlled study to assess the efficacy and safety of jinshuibao for patients with ckd due to glomerulonephritis, with a planned follow-up of 48 weeks.

previous studies have shown that cordyceps sinensis can act on several immune response pathways. jinshuibao capsule, which is composed of fermented cordyceps sinensis powder (cs-4) , has shown therapeutic effects in chronic kidney disease (ckd) according to small sample exploratory studies. here, we conduct a prospective, double-blind randomized controlled study to assess the efficacy and safety of jinshuibao for patients with ckd due to glomerulonephritis.

Eligibility criteria:
inclusion criteria: 1. aged \>= 18 years old and \<= 70 years old. 2. patients with chronic kidney disease caused by primary glomerulonephritis diagnosed by previous pathology or diagnosed by clinician. 3. chronic kidney disease stage 3b-4, that is, patients with egfr between 15 and 45 ml/min per 1.73 m2 (according to 2012 kdigo standard). 4. 24-hour urinary protein \< 3g during the screening period. 5. blood pressure, glucose, lipid and uric acid were measured during the screening period and were all in the following range: blood pressure: systolic blood pressure \<140 and diastolic blood pressure \< 90 mmhg; fasting blood-glucose \< 8.0mmol/l or hba1c \< 8.0%; ldll-c \< 100 mg /dl (2.59 mmol/l), and tc \< 230 mg /dl (5.95 mmol/l); uric acid \< 420 mol/l. 6. patients who have signed the informed consent. exclusion criteria: 1. pregnant or lactating women, or women of reproductive age who are unwilling to take reliable contraceptive measures. 2. allergy to jinshuibao. 3. treatment with natural cordyceps sinensis, artificial cordyceps sinensis, traditional chinese medicine or proprietary chinese medicine with known renal impairment in recent 2 weeks. 4. treatment with glucocorticoids, immunosuppressants or tripterygium wilfordii preparations in recent 3 months, or patients who have been confirmed to be treated with glucocorticoids, immunosuppressants or tripterygium wilfordii preparations in the following months. 5. history of gastrointestinal impairment or gastrointestinal diseases which may significantly affect the absorption of the experimental drugs, such as confirmed active ulcer (forrest grade ii or more severe impairment), inflammatory bowel disease, malabsorption syndrome, uncontrollable diarrhea or history of gastrointestinal surgery. 6. history of organ transplant, including kidney transplant. 7. history of severe diseases of the heart, brain, liver, hematopoietic system or other serious diseases affecting survival, such as malignant tumors, myocardial infarction, unstable angina, stroke or transient ischemic attack in recent 6 months. 8. patients whose disease progresses too rapidly judged by the clinician. 9. enrolled in other trials in recent 3 months. 10. patients who are assessed by investigator as unsuitable for inclusion.
phase 1b study of weekly carfilzomib in combination with lenalidomide and dexamethasone in subjects with multiple myeloma

Conditions: Multiple Myeloma

Summary: the purpose of the study is to assess the safety, tolerability and activity of a once-weekly regimen of carfilzomib in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma.


Eligibility criteria:
key inclusion criteria: 1. newly diagnosed or relapsed multiple myeloma 2. measureable disease by serum m protein, or urine m protein, or serum free light chain (sflc) and an abnormal serum kappa lambda ratio (for subjects without detectable serum or urine m-protein), or serum quantitative immunoglobulin a (glga) (for immunoglobulin (ig) a subjects whose disease can only be reliable measured by qlga). 3. eastern cooperative oncology group (ecog) performance status (ps) of 0 to 2 4. left ventricular ejection fraction (lvef) ≥ 40% key exclusion criteria: 1. waldenström macroglobulinemia 2. for newly diagnosed multiple myeloma: multiple myeloma of igm subtype 3. for relapsed disease: 1. if treated with a lenalidomide and dexamethasone combination, progression during the first 3 months after initiating treatment. 2. any progression during treatment if the lenalidomide and dexamethasone regimen was the most recent line of therapy. 3. any prior treatment with carfilzomib 4. poems syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes) 5. plasma cell leukemia (\> 2.0 × 10\^9/l circulating plasma cells by standard differential) 6. myelodysplastic syndrome 7. amyloidosis 8. prior treatment with carfilzomib or oprozomib